Core Insights - Genelux Corporation is advancing its late clinical-stage immuno-oncology product, Olvi-Vec, with significant clinical readouts expected in the coming year, particularly for platinum-resistant/refractory ovarian cancer [1][2][4] Pipeline Highlights - The Phase 3 OnPrime/GOG-3076 trial for Olvi-Vec in platinum-resistant/refractory ovarian cancer is on track, with topline data anticipated in the first half of 2026 [5] - Ongoing trials for small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) are expected to provide important data updates later this year, which may support the systemic delivery program of Olvi-Vec [2][5] Business Updates - The company appointed Eric Groen as General Counsel and Chief Compliance Officer, enhancing its leadership team with over 20 years of experience in the life sciences industry [3][6] - The CEO emphasized the potential of Olvi-Vec to redefine treatment paradigms for recurrent tumors and the company's growth phase [4] Financial Results - For Q2 2025, Genelux reported a net loss of $7.5 million, or $0.20 per share, compared to a net loss of $6.6 million, or $0.22 per share, in Q2 2024 [11][19] - Research and development expenses increased to $4.8 million from $4.4 million year-over-year, primarily due to higher clinical trial costs [10] - General and administrative expenses rose to $3.0 million from $2.5 million, driven by increased salaries and professional services [11] Cash Position - As of June 30, 2025, the company had cash, cash equivalents, and short-term investments totaling $28.1 million, expected to fund operations into Q3 2026 [9]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ GENELUX CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of Delaware 001-41599 77-0583529 Commissio ...

Genelux Corporation (GNLX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.T ...

Core Insights - Genelux Corporation reported a productive first quarter of 2025, establishing a strong foundation for advancing its lead product, Olvi-Vec, in various cancer indications [2][3] Pipeline Highlights - The FDA provided encouraging feedback on the OnPrime Phase 3 trial for Olvi-Vec in resistant/refractory ovarian cancer, indicating potential for traditional approval if a meaningful progression-free survival advantage is demonstrated [3] - Preliminary data from the Phase 1b/2 trial of Olvi-Vec in small cell lung cancer showed a 71% disease control rate, with significant tumor reductions observed in participants [4] - Patient enrollment is increasing in the ongoing Phase 2 trial for recurrent non-small cell lung cancer, with interim results expected in the second half of 2025 [5] Business Updates - Matthew Pulisic was appointed as the new Chief Financial Officer, bringing over 19 years of experience in the biopharmaceutical industry [6] - The company completed an underwritten offering of 3,000,000 shares at $3.50 per share, raising approximately $10.5 million to strengthen its balance sheet and extend its operational runway [7] Financial Results - As of March 31, 2025, cash, cash equivalents, and short-term investments totaled $35.1 million, expected to provide runway into the third quarter of 2026 [8] - Research and development expenses increased to $4.7 million from $4.0 million year-over-year, primarily due to higher clinical trial costs [9] - General and administrative expenses decreased to $3.1 million from $4.1 million year-over-year [10] - The net loss for the first quarter of 2025 was $7.5 million, or $0.21 per share, compared to a net loss of $7.9 million, or $0.29 per share, in the same period of 2024 [11]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ GENELUX CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of Delaware 001-41599 77-0583529 Commissi ...

Core Insights - Genelux Corporation is a late clinical-stage immuno-oncology company focused on developing next-generation oncolytic immunotherapies for aggressive and difficult-to-treat solid tumors [4] Group 1: Upcoming Events - Thomas Zindrick, President, CEO, and Chairman, along with Matt Pulisic, CFO, will discuss clinical-stage programs and milestones at the Citizens Life Sciences Conference on May 7-8, 2025 [1] - The conversation is scheduled for May 8, 2025, at 1:30 p.m. ET, and a webcast link will be available for the event [2] - The company will also hold one-on-one meetings during the conference for institutional investors interested in engaging with management [3] Group 2: Clinical Trials - Olvi-Vec is currently being evaluated in two U.S.-based clinical trials: OnPrime/GOG-3076, a Phase 3 trial for platinum-resistant/refractory ovarian cancer, and VIRO-25, a Phase 2 trial for non-small-cell lung cancer [4] - Additionally, Olvi-Vec is being assessed in a China-based Phase 1b trial for recurrent small-cell lung cancer [4] Group 3: Company Overview - Genelux's discovery and development efforts are centered around its proprietary CHOICE™ platform, which has led to a library of engineered oncolytic vaccinia virus immunotherapeutic candidates, including Olvi-Vec [4]

– Alignment reached with U.S. Food and Drug Administration on key elements of the approval pathway for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer – – Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer – – Matt Pulisic joined the company as its new Chief Financial Officer – – Closing of $10.5 Million Underwritten Offering of Common Stock – – $30.9 million in cash, cash equivalents and short-term investments – WESTLAKE VILLAGE, Calif., March 28, 2025 (GLOBE NEWSW ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41599 GENELUX CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Employer incorporation ...

Genelux Corporation (GNLX) has been on a downward spiral lately with significant selling pressure. After declining 29.7% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether ...

Financial Position - As of December 31, 2024, Genelux Corporation estimates its cash, cash equivalents, and short-term investments to be approximately $30.9 million[4]. - The Company has not yet completed its financial close process for the quarter and year ended December 31, 2024, and the preliminary cash estimate is subject to change[4]. - The corporate presentation made available on March 25, 2025, includes forward-looking statements regarding the Company's financial position and clinical trial outcomes[5]. Clinical Trials - In a Phase 1b clinical trial, 71% of evaluable participants (5 out of 7) achieved disease control with Olvi-Vec immunochemotherapy, showing tumor reductions ranging from 24% to 79%[11]. - The FDA indicated that a clinically meaningful progression-free survival advantage could support traditional approval for Olvi-Vec in treating platinum-resistant/refractory ovarian cancer[12]. - The Company anticipates reporting interim results from the Phase 2 VIRO-25 trial in the second half of 2025[14]. - Topline results from the Phase 3 OnPrime/GOG-3076 trial are expected to be reported in the first half of 2026[13]. - Treatment-related adverse events in the Olvi-Vec trial were mostly mild to moderate, with no maximum tolerated dose reached to date[8]. - The Company plans to provide an interim readout of updated data from the ongoing clinical trial in the second half of 2025[10]. - The FDA recommended a pre-BLA meeting to discuss next steps following the completion of the trial[12].